NC
CLDX icon

NewSquare Capital’s Celldex Therapeutics CLDX Stock Holding History

NewSquare Capital’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-115
Closed -$3.9K – 649
2023
Q2 		$3.9K Hold
115
– – ﹤0.01% 450
2023
Q1 		$4.14K Hold
115
– – ﹤0.01% 473
2022
Q4 		$5.13K Buy
+115
New +$4.11K ﹤0.01% 368

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

NewSquare Capital's CLDX Position: Q3 2023 in Review

NewSquare Capital sold out of Celldex Therapeutics (CLDX) in Q3 2023, closing a stake of 115 shares — an estimated $3.9K sold.

NewSquare Capital first reported a position in CLDX in Q4 2022 and held it in 3 quarters. The position peaked at $5.13K in Q4 2022. 144 funds tracked by Wall St. Rank hold CLDX as of Q3 2023.

  • NewSquare Capital reported no remaining Celldex Therapeutics position as of Q3 2023 after selling out during the quarter.
  • NewSquare Capital sold 115 Celldex Therapeutics shares in Q3 2023, an estimated $3.9K.
  • NewSquare Capital first reported a position in Celldex Therapeutics in Q4 2022 and held it in 3 quarters.
  • NewSquare Capital's Celldex Therapeutics position peaked at $5.13K in Q4 2022.
  • 144 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2023.

Based on NewSquare Capital's 13F filing for Q3 2023, filed 3 Nov 2023.